Day One Biopharmaceuticals Plans Q1 2025 Financial Report
Day One Biopharmaceuticals (NASDAQ: DAWN) is gearing up for a significant event. The biopharmaceutical company, known for its dedication to developing targeted therapies for serious illnesses, has announced a live conference call and webcast set for early May 2025. This event offers a chance for stakeholders to gain insight into the company’s financial performance and strategic initiatives.
Upcoming Conference Call Details
The conference call, scheduled for 4:30 p.m. ET on May 6, 2025, will allow the company's executives to share key financial results from the first quarter of the year. This session is particularly important as it will provide an update on Day One’s operational progress, ensuring investors and interested parties stay informed about the company’s trajectory in the biopharmaceutical landscape.
What to Expect During the Call
A live audio feed of the event will be available through the Day One Investors & Media page, along with an archived version for those unable to attend the live session. Investors are encouraged to tune in to hear about the latest updates, including potential developments in their product pipeline and partnerships.
About Day One Biopharmaceuticals
Founded with a mission to tackle the lack of treatment options in pediatric cancer, Day One Biopharmaceuticals is pioneering efforts in targeted cancer therapy. The company’s philosophy stems from “The Day One Talk,” where doctors converse with families about initial cancer treatment options. This foundational principle drives their innovative approach to drug development, focusing on redefining possibilities for all patients from day one of their diagnosis.
Innovative Therapeutic Pipeline
Day One is actively developing pivotal therapeutic solutions, with an impressive pipeline that includes treatments such as tovorafenib (OJEMDA™), DAY301, and a VRK1 inhibitor program. These therapies are designed specifically to meet the urgent needs of pediatric patients grappling with cancer, culminating in more personalized and effective treatments.
Strategic Collaborations and Partnerships
Collaboration plays a crucial role in Day One’s strategy. By partnering with leading oncologists, research scientists, and families affected by cancer, the company identifies and pursues the most promising approaches to treatment. This collaborative spirit enhances their ability to create targeted therapies that might one day change the landscape of pediatric oncology.
Company's Communication Channels
To keep investors engaged and informed, Day One utilizes various platforms, including their Investor Relations website. Their commitment to transparency is reflected in their regular updates about business performance and ongoing projects through channels like X and LinkedIn. This proactive communication strategy not only adheres to regulatory obligations but also fosters a sense of community among stakeholders.
Contact Information
For media inquiries, Laura Cooper, Head of Communications, is available at media@dayonebio.com. Investors can reach LifeSci Advisors representative, PJ Kelleher, at pkelleher@lifesciadvisors.com for more information or support.
Frequently Asked Questions
1. When will Day One Biopharmaceuticals report their financial results?
Day One Biopharmaceuticals is set to report their financial results on May 6, 2025.
2. How can stakeholders listen to the conference call?
Stakeholders can listen to the live conference call via the Day One Investors & Media page.
3. What is the mission of Day One Biopharmaceuticals?
The company's mission is to address critical gaps in pediatric cancer treatments and offer targeted therapies for affected children.
4. What types of therapies is Day One developing?
Day One’s pipeline includes tovorafenib (OJEMDA™), DAY301, and a VRK1 inhibitor program aimed at pediatric cancer.
5. Who can I contact for more information about investor relations?
For inquiries regarding investor relations, please contact PJ Kelleher from LifeSci Advisors at pkelleher@lifesciadvisors.com.
